Sonalasense Is A Clinical Stage Biotechnology Company Based In Oaklandcaliforniafounded In 2019The Company Focuses On Developing Sonodynamic Therapysdt A Noninvasive Treatment Method Aimed At Aggressive Cancersincluding Recurrent Glioblastoma Multiforme And Diffuse Intrinsic Pontine Gliomassonalasense Is Pioneering The Use Of Sdt In Clinical Trialssupported By A Significant $46 Million Award From Arpa H The Sdt Platform Combines Sonala 001A Tumor Targeting Drug Derived From Aminolevulinic Acidwith Mr Guided Focused Ultrasound To Selectively Destroy Cancer Cells While Preserving Healthy Tissuethis Innovative Approach Is Currently Being Tested In Clinical Trials For Various Cancersincluding Brain Tumors And Blood Cancerssonalasense Aims To Transform The Treatment Landscape For Cancer Patientsturning Lethal Conditions Into Manageable Ones Through Its Targeted And Noninvasive Technology
